CD33 and acute myeloid leukemia: Another study performed by Tambaro et al. (2021) described the treatment of R/R AML patients with autologous CAR-T cells modified to express a CD33-targeted CAR with 4-1BB and CD3ζ endo-domains and co-expressed with truncated human epidermal growth factor receptor (HER1t).